Epidermal growth factor receptor (EGFR) signaling in cancer.

By N. Normanno, A. De Luca, C. Bianco, L. Strizzi, M. Mancino, M. Maiello, A. Carotenuto, G. De Feo, F. Caponigro, D. Salomon. Gene, 2006

1,996 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/bbca62e28627954537456ef05dc41c2d41955dce

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Ping Wee
2. Zhixiang Wang

Citations in the corpus

• Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer (2021, background): “EGFR is expressed in almost all nonneoplastic cell types in TME, including CAFs, except mature cells in the lymphohematopoietic system.(245,246) GPER was first reported as a GPCR gene in breast cancer,(247) and Luo et al.”
• Targeting the EGFR signaling pathway in cancer therapy (2012, background): “activity of EGFR, HER2 and HER4 precludes HER3 signaling (Figure 1B) [14].”
• Protein Glycosylation in Cancer (2015, background): “Although cell surface receptors signal through a variety of mechanisms following ligand engagement, ligand-induced oligomerization of cell surface receptors reflects a common theme among receptors involved in regulating cell growth (153).”
• Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways (2017, background): “EGFR and ERBB4 both possess binding sites for SRC [109].”